Table 2 Frequency of progression stages grouped by visit
From: Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry
Baseline (n = 601) | FU 1 (n = 561) | FU 2 (n = 493) | FU 3 (n = 435) | FU 4 (n = 395) | FU 5 (n = 354) | FU 6 (n = 321) | FU 7 (n = 207) | FU 8 (n = 75) | FU 9 (n = 16) | FU 10 (n = 8) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Significant progression | 0 | 51 (8.7%) | 64 (12.4%) | 66 (14.4%) | 65 (15.7%) | 57 (15.5%) | 53 (16.1%) | 39 (17.4%) | 15 (19.0%) | 6 (35.3%) | 3 (33.3%) |
Moderate progression | 0 | 56 (9.5%) | 56 (10.9%) | 44 (9.6%) | 46 (11.1%) | 38 (10.3%) | 36 (10.9%) | 16 (7.1%) | 10 (12.7%) | 4 (23.5%) | 2 (22.2%) |
Stable | 561 (93.3%) | 201 (34.2%) | 145 (28.1%) | 123 (26.9%) | 103 (24.9%) | 83 (22.6%) | 63 (19.1%) | 44 (19.6%) | 20 (25.3%) | 4 (23.5%) | 2 (22.2%) |
Improve-ment | 0 | 103 (17.5%) | 93 (18.0%) | 91 (19.9%) | 61 (14.8%) | 52 (14.1%) | 57 (17.3%) | 30 (13.4%) | 5 (6.3%) | 1 (5.9%) | 0 |
PFT not done | 0 | 150 (25.6%) | 135 (26.2%) | 111 (24.3%) | 120 (29.1%) | 124 (33.7%) | 112 (33.9%) | 78 (34.8%) | 25 (31.6%) | 1 (5.9%) | 1 (11.1%) |